ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.04
0.60%
US Tech 100
17,446.00
2.17%
S&P 500
5,127.79
1.26%
US Dollar vs CAD
1.36685
0.00%
Bitcoin
63,208.68
-1.07%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MannKind Corporation (MNKD)

  7. MannKind Corporation (MNKD) News

MNKD

MannKind (MNKD)

MannKind Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MNKD
DateTimeSourceHeadlineSymbolCompany
05/01/20243:00PMGlobeNewswire Inc.MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024NASDAQ:MNKDMannKind Corporation
04/30/20245:05AMGlobeNewswire Inc.MannKind to Proceed With Phase 1 Nintedanib Dpi (Mnkd-201) Study for Pulmonary Fibrotic DiseasesNASDAQ:MNKDMannKind Corporation
04/29/20245:05AMGlobeNewswire Inc.MannKind Announces IND Clearance From U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial (NTM) Lung DiseaseNASDAQ:MNKDMannKind Corporation
04/03/20245:00AMGlobeNewswire Inc.MannKind Repays Certain Debt ObligationsNASDAQ:MNKDMannKind Corporation
03/26/20243:05PMGlobeNewswire Inc.MannKind Announces CFO TransitionNASDAQ:MNKDMannKind Corporation
03/11/20245:05AMGlobeNewswire Inc.INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin PumpsNASDAQ:MNKDMannKind Corporation
03/05/20245:05AMGlobeNewswire Inc.MannKind Announces New Clinical Data From Inhale-3 Study to be Presented by Dr. Irl B. Hirsch at ATTD on March 8NASDAQ:MNKDMannKind Corporation
03/04/202412:01PMGlobeNewswire Inc.MannKind Corporation Announces Participation at Upcoming ConferencesNASDAQ:MNKDMannKind Corporation
02/27/20243:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
02/27/20243:00PMGlobeNewswire Inc.MannKind Corporation Reports 2023 Fourth Quarter and Full Year Financial Results: Provides Clinical Development UpdateNASDAQ:MNKDMannKind Corporation
02/20/20245:00AMGlobeNewswire Inc.MannKind Corporation to Hold 2023 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2024NASDAQ:MNKDMannKind Corporation
02/15/20245:05AMGlobeNewswire Inc.MannKind Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®NASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
02/05/20245:00AMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
01/02/20245:06AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
01/02/20245:05AMGlobeNewswire Inc.MannKind and Sagard Healthcare Enter Into Royalty Purchase Agreement for Up to $200 MillionNASDAQ:MNKDMannKind Corporation
12/28/20235:00AMGlobeNewswire Inc.MannKind Corporation to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:MNKDMannKind Corporation
12/27/20233:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
12/15/20238:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
12/15/20233:09PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
12/14/20236:56PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
12/14/20233:08PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:MNKDMannKind Corporation
11/07/20233:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MNKDMannKind Corporation
11/07/20233:00PMGlobeNewswire Inc.MannKind Corporation Reports 2023 Third Quarter Financial ResultsNASDAQ:MNKDMannKind Corporation
11/06/20235:15AMGlobeNewswire Inc.MannKind Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living With Type 1 DiabetesNASDAQ:MNKDMannKind Corporation
11/02/20238:00PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MNKDMannKind Corporation
 Showing the most relevant articles for your search:NASDAQ:MNKD

Your Recent History

USOTC
ZHUD
Zhuding (PK)
USOTC
CYDY
CytoDyn (QB)
COIN
SHIBUSD
SHIBA INU
USOTC
CGAC
Code Green Apparel (PK)
USOTC
SPZI
Spooz (PK)
USOTC
KEGS
1812 Brewing (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RNVA
Rennova Health (PK)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
DBMM
Digital Brand Media and ... (PK)
NASDAQ
DJT
Trump Media and Technology
USOTC
IFUS
Impact Fusion (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
NASDAQ
COOP
Mr Cooper
USOTC
IGPK
Intergrated Cannabis Sol... (PK)
USOTC
NWBO
Northwest Biotherapeutics (QB)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved